Home / Current Issue / Paper 1722189
The Enzymatic Gatekeepers of Glycemic Flux: Revisiting α-Amylase and α-Glucosidase Inhibition as a Cornerstone of Integrative Diabetes Management
Subject area: Science,Engineering and Technology · Area of research: Biochemistry and Toxicology
DOI: https://doi.org/10.64388/IREV5I9-1722189
Abstract
Type 2 Diabetes Mellitus (T2DM) has emerged as one of the most significant public health crises of the 21st century, primarily characterized by postprandial hyperglycemia resulting from impaired insulin dynamics. A key therapeutic strategy is to slow carbohydrate digestion by inhibiting α-amylase and α-glucosidase. This study examines the structural biochemistry of these enzymes and evaluates the efficacy of current pharmacological inhibitors, including acarbose, miglitol, and voglibose. Projections indicate a global prevalence of 7,079 cases per 100,000 population by 2030, necessitating more effective and safer therapeutic interventions. Using in vitro enzymatic assays, including the dinitrosalicylic acid method and p-nitrophenyl glucopyranoside (pNPG) analysis, we investigate the inhibitory potential of both synthetic and natural compounds. The research shows that while synthetic inhibitors effectively reduce HbA1c by 0.5–1.4%, significant gastrointestinal side effects limit their use. Natural phytochemicals, such as rosmarinic acid and eriodictyol, exhibit higher binding affinities in molecular docking studies than acarbose, offering a promising, milder inhibitory approach. This comprehensive review consolidates the current understanding of enzyme inhibition as a cornerstone of glucose homeostasis management.
Keywords
Type 2 Diabetes Mellitus, α-Amylase, α-Glucosidase, Acarbose, Phytochemicals, Rosmarinic Acid, Molecular Docking, Postprandial Hyperglycemia, Enzyme Inhibition.
How to cite this paper
@article{1722189,
author = {Bada, Sunday O.},
title = {The Enzymatic Gatekeepers of Glycemic Flux: Revisiting α-Amylase and α-Glucosidase Inhibition as a Cornerstone of Integrative Diabetes Management},
journal = {Iconic Research And Engineering Journals},
year = {2022},
volume = {5},
number = {9},
pages = {815-830},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1722189.pdf},
abstract = {Type 2 Diabetes Mellitus (T2DM) has emerged as one of the most significant public health crises of the 21st century, primarily characterized by postprandial hyperglycemia resulting from impaired insulin dynamics. A key therapeutic strategy is to slow carbohydrate digestion by inhibiting α-amylase and α-glucosidase. This study examines the structural biochemistry of these enzymes and evaluates the efficacy of current pharmacological inhibitors, including acarbose, miglitol, and voglibose. Projections indicate a global prevalence of 7,079 cases per 100,000 population by 2030, necessitating more effective and safer therapeutic interventions. Using in vitro enzymatic assays, including the dinitrosalicylic acid method and p-nitrophenyl glucopyranoside (pNPG) analysis, we investigate the inhibitory potential of both synthetic and natural compounds. The research shows that while synthetic inhibitors effectively reduce HbA1c by 0.5–1.4%, significant gastrointestinal side effects limit their use. Natural phytochemicals, such as rosmarinic acid and eriodictyol, exhibit higher binding affinities in molecular docking studies than acarbose, offering a promising, milder inhibitory approach. This comprehensive review consolidates the current understanding of enzyme inhibition as a cornerstone of glucose homeostasis management.},
keywords = {Type 2 Diabetes Mellitus, α-Amylase, α-Glucosidase, Acarbose, Phytochemicals, Rosmarinic Acid, Molecular Docking, Postprandial Hyperglycemia, Enzyme Inhibition.},
month = {March},
doi = {https://doi.org/10.64388/IREV5I9-1722189}
}